More Stories

Informist, Thursday, Jul. 30, 2026

 

Please click here to read all liners published on this story

--Torrent Pharma Apr-Jun consol net profit INR 5.66 bln 
--Analysts saw Torrent Pharma Apr-Jun consol net profit at INR 5.37 bln 
--Torrent Pharma Apr-Jun consol revenue INR 49.21 bln 
--Analysts saw Torrent Pharma Apr-Jun consol revenue at INR 45.61 bln 
--Torrent Pharma Apr-Jun consol PAT INR 5.66 bln vs INR 5.48 bln year ago 
--Torrent Pharma Apr-Jun consol revenue INR 49.21 bln vs INR 31.78 bln yr ago 
--Torrent Pharma Q1 consol operating EBITDA INR 16.64 bln, up 61% on year 
--Torrent Pharma Q1 consol operating EBITDA margin 33.8% vs 32.5% yr ago 
--Torrent Pharma Q1 consol R&D spend INR 1.72 bln vs INR 1.57 bln yr ago 
--Torrent Pharma Apr-Jun India revenue INR 21.57 bln, up 19% on yr 
--Torrent Pharma Apr-Jun Brazil revenue INR 2.77 bln, up 27% on yr 
--Torrent Pharma Apr-Jun US business revenue INR 4.18 bln, up 36% on yr 
--Torrent Pharma Apr-Jun Germany revenue INR 3.18 bln, up 3% on yr 
--Torrent Pharma Apr-Jun US sales up 23% YoY in constant currency 

 

By Diksha Tripathy and Ruchira Kagita

 

MUMBAI – Torrent Pharmaceuticals Ltd. reported record year-on-year growth in its consolidated revenue for the June quarter. The company's sales and profit beat the consensus expectations. Growth in its domestic business outpaced that of the Indian pharmaceutical market.

 

The pharmaceuticals company reported a consolidated net profit of INR 5.66 billion, up over 3% on year, for the June quarter, higher than the Street's estimates of INR 5.37 billion. The company's consolidated revenue for the first quarter of the financial year 2026-27 (Apr-Mar) was up over 54% on year to INR 49.21 billion, against INR 31.78 billion in the year-ago quarter. Analysts had estimated the company's consolidated revenue at INR 45.61 billion.

 

Torrent Pharma's revenue from India operations rose 19% on year to INR 21.57 billion. The generic semaglutide segment recorded a market share of 36%, including oral and injectable versions of the drug, the company said in a press release. The Indian pharmaceutical market grew 12% for the quarter, the company said, citing data from AIOCD Pharmatrac.

 

The Torrent group's pharmaceutical business posted 13% year-on-year rise in prescription sales to INR 6.57 billion. This excludes its trade generics and contrast media segments. The company's international revenue for the June quarter was INR 19.19 billion. Meanwhile, sales from its contract development and manufacturing organisation vertical climbed 27% to INR 1.45 billion.

 

Torrent Pharma had merged J.B. Chemicals & Pharmaceuticals Ltd. with itself effective Jul. 17 and the company's consolidated financial results for the June quarter have been adjusted to include the standalone financials of J.B. Chemicals. The domestic sales of J.B. Chemicals were INR 7.33 billion, which is 34% of Torrent Pharma's overall India revenue. The subsidiary contributed sales of INR 4.68 billion to Torrent Pharma's international revenue.

 

Torrent Pharma's revenues from the US inched up 36% on year to INR 4.18 billion and by 23% in constant currency to $44 million. Sales from its second-largest market, Germany, increased 3% for the period to INR 3.18 billion. However, revenue from the region in constant currency slipped on a year-on-year basis owing to supply disruption at a third-party supplier and lower offtake in a tender. Revenue in constant currency was down 9% at 29 million euros (about INR 3.19 billion).

 

The company's sales from Brazil rose 27% on year to INR 2.77 billion and by 3% in constant currency to 147 Brazilian reals (INR 2.75 billion). As in India, Torrent Pharma outperformed the South American country's pharmaceutical market. The India-headquartered company posted 21% growth for the June quarter when the overall market in Brazil expanded by 5%. Torrent Pharma trimmed its inventory down in response to channel requests for the same, it said in the press release.

 

Torrent Pharma's total expenses for the quarter ended June rose almost 73% year-on-year to INR 41.55 billion. Other expenses, which came in at INR 12.01 billion, made up most of the company's spend. Expenditure under this head rose by about 57% for the quarter. Meanwhile, the expenses related to employee benefits and raw materials consumed went up by 48% and 54%, respectively. Costs pertaining to stock-in-trade rose 57% to INR 53.10 billion. 

 

The company's spending on research and development as a share of overall revenue slipped to 4% from 5% in the corresponding quarter a year ago. Its spending for this purpose during the June quarter was INR 1.72 billion, against INR 1.57 billion in the year-ago quarter.

 

Torrent Pharma's net operating earnings before interest, taxes, depreciation, and amortisation increased 61% on year to INR 16.64 billion for the quarter in focus. Its EBITDA margin was 33.8%, up by 130 basis points. The company, meanwhile, reported a gross margin of 76.4% for the June quarter.

The pharmaceutical company released its earnings for the June quarter after trading hours. Thursday, its shares closed slightly lower from Wednesday at INR 4,872.10 on the National Stock Exchange.  End

 

US$1 = INR 95.68

 

Edited by Rajeev Pai

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000 

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.